Found this on the internet.
OxyPharma Announces Selection of Multiple Sclerosis (MS) Drug Development Candidate
STOCKHOLM, Sweden, April 5, 2005--Swedish drug development company OxyPharma has selected a candidate drug (CD) for the treatment of multiple sclerosis (MS) from its autoimmune diseases drug discovery program. The selected compound, Rob 895, is now ready to go into a full-scale pre-clinical program.
Rob 895 has been developed from OxyPharma's patented lead compound B-220, from which OxyPharma has developed ...